SELF-ADMINISTERED etripamil, an intranasal calcium channel blocker, significantly reduces emergency department (ED) visits ...

The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT). The FDA highlighted two key Chemistry, Manufacturing ...

PSVT is a type of arrhythmia causing rapid heartbeat in areas of the heart above the ventricles, and is caused by abnormal electrical pathways in the heart. It can cause dizziness, palpitations ...

USA: A recent study published in JAMA Cardiology revealed that self-administered etripamil was almost twice as effective as ...

"We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...

Findings showed a higher proportion of patients in the etripamil group achieved PSVT conversion to sinus rhythm within 30 minutes compared with those who received placebo. Etripamil was also ...

Paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF): 50mg every 12 hours; increase in increments of 50mg twice daily every 4 days until efficacy is ...